{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:53:34Z","timestamp":1767167614703,"version":"build-2238731810"},"reference-count":53,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/501100017515","name":"Heidelberger Stiftung Chirurgie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017515","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,7,8]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pancreatic cancer is a devastating disease with an exceptionally poor prognosis. Complete resection of the primary tumour followed by adjuvant chemotherapy is the current standard treatment for patients with resectable disease and the only curative treatment option. However, long-term survival remains rare. Tumour cell dissemination due to manipulation during surgery may increase the rate of future metastases and local recurrence, and perioperative chemotherapy might diminish local, distant and circulating minimal residual disease. Yet, safety and feasibility of systemic chemotherapeutic treatments during pancreatic cancer resection have to be evaluated in a first instance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This is a prospective, single-centre phase I\/II feasibility study to investigate the safety and tolerability of a combination of intraoperative chemotherapy and surgical resection in pancreatic cancer. Forty patients with locally confined or borderline resectable pancreatic cancer, meeting all proposed criteria will be included. Participants will receive 400\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      calcium folinate over 2\u2009hours and 2000\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      5-fluorouracil over 48\u2009hours, started on the day before pancreatic surgery and thus continuing during surgery. Participants will be followed until 60 days after surgery. The primary endpoint is the 30-day overall complication rate according to the Clavien-Dindo classification. Secondary endpoints comprise toxicity and treatment associated complications. Patients receiving perioperative chemotherapy will be compared with a propensity score matched contemporary control group of 70 patients with pancreatic cancer receiving the standard treatment. This trial also contains an ancillary translational study to analyse disseminated tumour cells and effects of pharmacological interventions in pancreatic cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>CombiCaRe has been approved by the German Federal Institute for Drugs and Medical Devices (reference number 4042787) and the Medical Ethics Committee of Heidelberg University (reference number AFmo-269\/2018). The results of this trial will be presented at national and international conferences and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>German Clinical Trials Register (DRKS00015766).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-028696","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T06:05:28Z","timestamp":1566367528000},"page":"e028696","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Protocol of a prospective, monocentric phase I\/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study"],"prefix":"10.1136","volume":"9","author":[{"given":"Susanne","family":"Roth","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Tumor Diseases (NCT) and Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus K","family":"Diener","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Tjaden","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Knebel","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Klaiber","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph W","family":"Michalski","sequence":"additional","affiliation":[{"name":"Department of Visceral, Vascular and Endocrine Surgery, Universit\u00e4tsklinikum Halle, Halle, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Mieth","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Tumor Diseases (NCT) and Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus W","family":"B\u00fcchler","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilo","family":"Hackert","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"key":"2025101811265435000_9.8.e028696.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"2025101811265435000_9.8.e028696.2","doi-asserted-by":"crossref","unstructured":"Kleeff J , Korc M , Apte M , et al . Pancreatic cancer. Nat Rev Dis Primers 2016;2.doi:10.1038\/nrdp.2016.22","DOI":"10.1038\/nrdp.2016.22"},{"key":"2025101811265435000_9.8.e028696.3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.pan.2018.09.012","article-title":"Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National Institute for health and care excellence","volume":"18","author":"O'Reilly","year":"2018","journal-title":"Pancreatology"},{"key":"2025101811265435000_9.8.e028696.4","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1200\/JCO.2017.72.4948","article-title":"Potentially curable pancreatic cancer: American Society of clinical oncology clinical practice guideline update","volume":"35","author":"Khorana","year":"2017","journal-title":"JCO"},{"key":"2025101811265435000_9.8.e028696.5","first-page":"1395","article-title":"[S3-guideline exocrine pancreatic cancer]","volume":"51","author":"Seufferlein","year":"2013","journal-title":"Z Gastroenterol"},{"key":"2025101811265435000_9.8.e028696.6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0131"},{"key":"2025101811265435000_9.8.e028696.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2014.02.001"},{"key":"2025101811265435000_9.8.e028696.8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"2025101811265435000_9.8.e028696.9","first-page":"255","article-title":"Pancreatic cancer-low survival rates","volume":"105","author":"Beger","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"2025101811265435000_9.8.e028696.10","doi-asserted-by":"publisher","DOI":"10.1159\/000347178"},{"key":"2025101811265435000_9.8.e028696.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70172-4"},{"key":"2025101811265435000_9.8.e028696.12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3180691579"},{"key":"2025101811265435000_9.8.e028696.13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"2025101811265435000_9.8.e028696.14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"The Lancet"},{"key":"2025101811265435000_9.8.e028696.15","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1985.01390320023003"},{"key":"2025101811265435000_9.8.e028696.16","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199912000-00006"},{"key":"2025101811265435000_9.8.e028696.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06651-X"},{"key":"2025101811265435000_9.8.e028696.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1275"},{"key":"2025101811265435000_9.8.e028696.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032295"},{"key":"2025101811265435000_9.8.e028696.20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604838"},{"key":"2025101811265435000_9.8.e028696.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.3.267"},{"key":"2025101811265435000_9.8.e028696.22","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1630-6"},{"key":"2025101811265435000_9.8.e028696.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.9.1019"},{"key":"2025101811265435000_9.8.e028696.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.2960"},{"key":"2025101811265435000_9.8.e028696.25","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"JCO"},{"key":"2025101811265435000_9.8.e028696.26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann Surg"},{"key":"2025101811265435000_9.8.e028696.27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"2025101811265435000_9.8.e028696.28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.surg.2016.08.040","article-title":"Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: a nationwide propensity score matched analysis","volume":"161","author":"de Geus","year":"2017","journal-title":"Surgery"},{"key":"2025101811265435000_9.8.e028696.29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","article-title":"Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis","volume":"35","author":"Mokdad","year":"2017","journal-title":"JCO"},{"key":"2025101811265435000_9.8.e028696.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0903048"},{"key":"2025101811265435000_9.8.e028696.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2009.01.019"},{"key":"2025101811265435000_9.8.e028696.32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/SLA.0000000000002248","article-title":"Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany","volume":"267","author":"Krautz","year":"2018","journal-title":"Ann Surg"},{"key":"2025101811265435000_9.8.e028696.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2005.05.001"},{"key":"2025101811265435000_9.8.e028696.34","unstructured":"Bassi C , Marchegiani G , Dervenis C , et al . The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2016."},{"key":"2025101811265435000_9.8.e028696.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2007.05.005"},{"key":"2025101811265435000_9.8.e028696.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2007.02.001"},{"key":"2025101811265435000_9.8.e028696.37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.surg.2016.06.058","article-title":"Definition and classification of chyle leak after pancreatic operation: a consensus statement by the International Study Group on pancreatic surgery","volume":"161","author":"Besselink","year":"2017","journal-title":"Surgery"},{"key":"2025101811265435000_9.8.e028696.38","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6"},{"key":"2025101811265435000_9.8.e028696.39","doi-asserted-by":"publisher","DOI":"10.1007\/s002689900215"},{"key":"2025101811265435000_9.8.e028696.40","first-page":"1500","article-title":"Pancreatic liver metastases after curative resection combined with intraoperative radiation for pancreatic cancer","volume":"51","author":"Takamori","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"2025101811265435000_9.8.e028696.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.11.060"},{"key":"2025101811265435000_9.8.e028696.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.11.025"},{"key":"2025101811265435000_9.8.e028696.43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-4613-1247-5_6","article-title":"Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology","volume":"82","author":"Sugarbaker","year":"1996","journal-title":"Cancer Treat Res"},{"key":"2025101811265435000_9.8.e028696.44","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamasurg.2013.3643","article-title":"Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer","volume":"149","author":"Gall","year":"2014","journal-title":"JAMA Surg"},{"key":"2025101811265435000_9.8.e028696.45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1245\/s10434-017-6290-8","article-title":"Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer","volume":"25","author":"Court","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2025101811265435000_9.8.e028696.46","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/SLA.0000000000002925","article-title":"Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective cluster study","volume":"268","author":"Gemenetzis","year":"2018","journal-title":"Ann Surg"},{"key":"2025101811265435000_9.8.e028696.47","doi-asserted-by":"crossref","unstructured":"Hugenschmidt H , Labori KJ , Brunborg C , et al . Circulating tumor cells are an independent predictor of shorter survival in patients undergoing resection for pancreatic and periampullary adenocarcinoma. Ann Surg 2018:1.doi:10.1097\/SLA.0000000000003035","DOI":"10.1097\/SLA.0000000000003035"},{"key":"2025101811265435000_9.8.e028696.48","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/676585"},{"key":"2025101811265435000_9.8.e028696.49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00423-013-1144-8","article-title":"Surgical treatment of peritoneal carcinomatosis: current treatment modalities","volume":"399","author":"Kulu","year":"2014","journal-title":"Langenbecks Arch Surg"},{"key":"2025101811265435000_9.8.e028696.50","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1245\/s10434-016-5096-4","article-title":"Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin in the era of value-based medicine","volume":"23","author":"Vanounou","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025101811265435000_9.8.e028696.51","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1384-6"},{"key":"2025101811265435000_9.8.e028696.52","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025101811265435000_9.8.e028696.53","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2018-028696corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-028696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:27:07Z","timestamp":1760812027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-028696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,20]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bmjopen-2018-028696"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-028696","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}